M
MLYS
Mineralys Therapeutics, Inc.
27.76
-0.55-1.94%After Hours: 27.76 0.00 0.00%16:10 04/08 EDT
OPEN/PREV CLOSE27.76/28.31
TODAY RANGE27.49-29.78
VOL836.69K
MARKET CAP2.29B
52 WEEK RANGE10.44-47.65
AVG VOL (3M)1.27M
% TURNOVER1.02%
TURNOVER--
P/E (TTM)-12.1445
% RANGE8.09%
EPS(TTM)-2.2858
P/E(FORWARD)-12.8519
P/B3.500
BVPS7.93
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.18B
SHARES OUTSTANDING82.40M
NEXT EARNINGS05/11-05/15
FREE FLOAT78.41M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·15h ago
A Look At Mineralys Therapeutics (MLYS) Valuation After FDA Accepts Lorundrostat NDA For Hypertension
Simply Wall St·6d ago
Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires?
TipRanks·04/01 02:01
Major Insider Power Move Signals Growing Confidence in Mineralys Therapeutics
Reuters·03/31 20:21
RA Capital Management acquires $8.8 million Mineralys Therapeutics shares
NASDAQ·03/31 19:19
Notable Tuesday Option Activity: MLYS, DELL, SGHC
TipRanks·03/31 11:08
Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board
Reuters·03/31 10:55
BUZZ-Immunic rises after board hire of MS drug veteran
Reuters·03/24 12:03
Mineralys appoints Jeffrey A. Munsie as chief legal officer
Reuters·03/24 12:00
MINERALYS THERAPEUTICS APPOINTS JEFFREY A. MUNSIE AS CHIEF LEGAL OFFICER
Simply Wall St·03/23 06:09
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed
NASDAQ·03/20 12:46
The Math Shows FTLS Can Go To $84
Same Industry
Name/Symbol
Change%
Price